Latest Acura Pharmaceuticals (ACUR) Headlines A
Post# of 16
Posted On: 03/13/2014 4:47:38 AM
Latest Acura Pharmaceuticals (ACUR) Headlines
Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.
Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.
Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.
Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.
Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
4 Stocks Under $10 Moving Higher
at The Street - Fri Feb 14, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Acura Confirms $10M Loan Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 6:05PM CST
Acura confirmed a $10 million debt financing from Oxford Finance.
Acura Pharmaceuticals secures USD10m term loan from Oxford Financing
M2 - Tue Dec 31, 6:07AM CST
Specialty pharmaceutical company Acura Pharmaceuticals Inc (Nasdaq:ACUR) announced on Monday that it has entered into a loan and security agreement with Oxford Finance LLC, under which Oxford has agreed to make a term loan to the company of USD10m in principal amount.
Acura Pharmaceuticals Secures $10.0 Million of Debt Financing
Marketwire - Mon Dec 30, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $10.0 million. The loan has a fixed interest rate of 8.35% per annum with interest only payment for the first 15 months and repayment of all principal and interest by December 1, 2018. In addition, at maturity or earlier termination, the Company must pay Oxford an additional one-time interest payment of $795,000. As security for its obligations under the Loan Agreement, the Company granted Oxford a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. The Company may use the proceeds of the Loan Agreement for general working capital and to fund its business requirements.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
Acura Pharma and FDA discuss anti-abuse pain pill
AP - Mon Dec 09, 12:22PM CST
WASHINGTON (AP) — Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology
ACCESSWIRE - Mon Dec 09, 10:00AM CST
New York, December 09, 2013 /Accesswire/ - Market Buzz Report, a leading penny stock newsletters provider, issues major news alert for Gilead Sciences, Inc.(NASDAQ:GILD), Acura Pharmaceuticals, Inc.(NASDAQ:ACUR), Barnes & Noble, Inc.(NYSE:BKS), Micron Technology, Inc. (NASDAQ:MU).
Acura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug Development
Marketwire - Mon Dec 09, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that it met on December 5th with the U.S. Food and Drug Administration (FDA) to review the results of Acura's Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug abusers assessing the abuse liability of snorting a crushed hydrocodone bitartrate with acetaminophen tablet formulated with Acura's abuse deterrent AVERSION technology (AVERSION H&A). The primary purpose of the meeting was to discuss if the FDA will consider whether the results of Study 301 are acceptable for submission in a New Drug Application (NDA). The meeting was designated a pre-NDA meeting.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Morning Research: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharma Inc.
PR Newswire - Wed Nov 06, 8:22AM CST
Editor Note: For more information about this release, please scroll to bottom.
Acura Pharmaceuticals Inc's 30 mg immediate-release pseudoephedrine (Nexafed) to be distributed by Rite Aid Pharmacies
M2 - Tue Nov 05, 4:40AM CST
Pharmaceutical company Acura Pharmaceuticals Inc (NASDAQ:ACUR) said on Monday that NEXAFED will now be stocked by Rite Aid Pharmacies.
Acura Pharmaceuticals Announces Third Quarter 2013 Financial Results
Marketwire - Mon Nov 04, 4:04PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2013.
Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference
Marketwire - Wed Mar 05, 1:00PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.
Stock to Watch: Acura Pharmaceuticals Down 9.6% (ACUR)
Comtex SmarTrend(R) - Tue Mar 04, 10:12AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's worst performing low-priced stocks, down 9.6% to $1.78 on 2.2x average daily volume. Thus far today, Acura Pharmaceuticals has traded 736,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's 1.2%) and underperformed the S&P 500 (-9.6% to the S&P's 1.3%) during today's trading.
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Mon Mar 03, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.
Acura Pharmaceuticals Up 6.2%, Shares Break Through Resistance (ACUR)
Comtex SmarTrend(R) - Thu Feb 27, 11:40AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 6.2% to $2.06 on 3.4x average daily volume. Acura Pharmaceuticals has traded 972,000 shares thus far today, vs. average volume of 285,000 shares per day. The stock has outperformed the Dow (6.2% to the Dow's 0.2%) and outperformed the S&P 500 (6.2% to the S&P's 0.2%) during today's trading.
Acura Pharmaceuticals to Host 2013 Financial Results Conference Call on March 4, 2014
Marketwire - Tue Feb 18, 3:05PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for 2013 following the close of financial markets on Monday, March 3, 2014. The Company will host a conference call to discuss the results on Tuesday, March 4, 2014 at 8:30 a.m. ET.
Stock to Watch: Acura Pharmaceuticals Up 8.6% (ACUR)
Comtex SmarTrend(R) - Tue Feb 18, 10:11AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 8.6% to $2.01 on 5.5x average daily volume. Acura Pharmaceuticals has traded 1.1 million shares thus far today, vs. average volume of 208,000 shares per day. The stock has outperformed the Dow (8.6% to the Dow's -0.1%) and outperformed the S&P 500 (8.6% to the S&P's 0.1%) during today's trading.
Acura Pharmaceuticals, Inc. (ACUR) Looks Good: Stock Adds 5.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 7:44AM CST
Acura Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise 5% on the day.
Traders Get Bullish on Shares of Acura Pharmaceuticals, Shares Up 5.7% (ACUR)
Comtex SmarTrend(R) - Fri Feb 14, 10:41AM CST
Acura Pharmaceuticals (NASDAQ:ACUR) is one of today's best performing low-priced stocks, up 5.7% to $1.86 on 3.5x average daily volume. Acura Pharmaceuticals has traded 736,000 shares thus far today, vs. average volume of 210,000 shares per day. The stock has outperformed the Dow (5.7% to the Dow's 0.4%) and outperformed the S&P 500 (5.7% to the S&P's 0.2%) during today's trading.
4 Stocks Under $10 Moving Higher
at The Street - Fri Feb 14, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Acura Confirms $10M Loan Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 6:05PM CST
Acura confirmed a $10 million debt financing from Oxford Finance.
Acura Pharmaceuticals secures USD10m term loan from Oxford Financing
M2 - Tue Dec 31, 6:07AM CST
Specialty pharmaceutical company Acura Pharmaceuticals Inc (Nasdaq:ACUR) announced on Monday that it has entered into a loan and security agreement with Oxford Finance LLC, under which Oxford has agreed to make a term loan to the company of USD10m in principal amount.
Acura Pharmaceuticals Secures $10.0 Million of Debt Financing
Marketwire - Mon Dec 30, 3:10PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the Company in the principal amount of $10.0 million. The loan has a fixed interest rate of 8.35% per annum with interest only payment for the first 15 months and repayment of all principal and interest by December 1, 2018. In addition, at maturity or earlier termination, the Company must pay Oxford an additional one-time interest payment of $795,000. As security for its obligations under the Loan Agreement, the Company granted Oxford a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. The Company may use the proceeds of the Loan Agreement for general working capital and to fund its business requirements.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
Acura Pharma and FDA discuss anti-abuse pain pill
AP - Mon Dec 09, 12:22PM CST
WASHINGTON (AP) — Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology
ACCESSWIRE - Mon Dec 09, 10:00AM CST
New York, December 09, 2013 /Accesswire/ - Market Buzz Report, a leading penny stock newsletters provider, issues major news alert for Gilead Sciences, Inc.(NASDAQ:GILD), Acura Pharmaceuticals, Inc.(NASDAQ:ACUR), Barnes & Noble, Inc.(NYSE:BKS), Micron Technology, Inc. (NASDAQ:MU).
Acura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug Development
Marketwire - Mon Dec 09, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that it met on December 5th with the U.S. Food and Drug Administration (FDA) to review the results of Acura's Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug abusers assessing the abuse liability of snorting a crushed hydrocodone bitartrate with acetaminophen tablet formulated with Acura's abuse deterrent AVERSION technology (AVERSION H&A). The primary purpose of the meeting was to discuss if the FDA will consider whether the results of Study 301 are acceptable for submission in a New Drug Application (NDA). The meeting was designated a pre-NDA meeting.
Global Opium (Opioid) Addiction Global Clinical Trials Review Report - H2 2013 Edition
M2 - Fri Nov 22, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/92tp9r/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" report to their offering. Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid) Addiction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opium (Opioid) Addiction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opium (Opioid) Addiction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Universities Participating in Opium (Opioid) Addiction Therapeutics Clinical Trials - Reckitt Benckiser Group Plc - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Butler Hospital - Johns Hopkins University - Lightlake Therapeutics Inc. - National Institute on Drug Abuse - New York State Psychiatric Institute - Omeros Corporation - Orexo AB - Pfizer Inc. - The Langton Centre - The University of Chicago - Titan Pharmaceuticals, Inc. - US WorldMeds, LLC - University of California, Los Angeles - University of California, San Francisco - University of Pennsylvania - Yale University For more information visit http://www.researchandmarkets.com/research/92...ium_opioid
Morning Research: VIVUS Inc., Sanofi, DENTSPLY Intl. Inc., and Acura Pharma Inc.
PR Newswire - Wed Nov 06, 8:22AM CST
Editor Note: For more information about this release, please scroll to bottom.
Acura Pharmaceuticals Inc's 30 mg immediate-release pseudoephedrine (Nexafed) to be distributed by Rite Aid Pharmacies
M2 - Tue Nov 05, 4:40AM CST
Pharmaceutical company Acura Pharmaceuticals Inc (NASDAQ:ACUR) said on Monday that NEXAFED will now be stocked by Rite Aid Pharmacies.
Acura Pharmaceuticals Announces Third Quarter 2013 Financial Results
Marketwire - Mon Nov 04, 4:04PM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2013.
(0)
(0)Acura Pharmaceuticals Inc. (ACUR) Stock Research Links
Scroll down for more posts ▼